Chuqi Ye

Maxygen (United States)

Papers

1

Total Citations

60

H-Index

1

About

Chuqi Ye is a distinguished researcher in pharmaceutical analysis and drug metabolism, with a primary focus on the bioanalytical quantification of tyrosine kinase inhibitors. Their most cited work, a 2003 study on the quantitation of SU11248 (sunitinib) and its metabolite in monkey tissues, has garnered 60 citations, establishing a foundational methodology for the pharmacokinetic assessment of this critical oral multi-target cancer therapy. Ye’s major contribution lies in the development of a robust, semi-automated liquid-liquid extraction technique coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS), which enabled precise, high-throughput analysis of drug distribution in complex biological matrices. This work not only advanced the preclinical understanding of sunitinib’s tissue disposition but also set a standard for bioanalytical methods in targeted oncology drug development. By providing a reliable framework for quantifying both parent drug and active metabolite, Ye’s research has directly supported the translational safety and efficacy profiling of multi-kinase inhibitors, impacting subsequent clinical studies and therapeutic monitoring. Their meticulous approach to analytical chemistry continues to inform best practices in pharmaceutical bioanalysis.

Research Focus

Key Achievements

1
H-Index
1
Papers
60
Total Citations
60
Avg Citations/Paper
🏆 Most Cited Paper
Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid–liquid extraction
60 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Maxygen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago